Growth In ANDA Submissions Is Leveling Off, OGD Director Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While still growing and setting records, change in pace of submissions could give FDA "breather" to work on backlog.
You may also be interested in...
First Generic User Fees Proposed By Deputy Commissioner Gottlieb
GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.
AstraZeneca Joins The $35 Inhaler Club; Medicare Patients Waiting On Congress For Membership
AZ’s move follows Boehringer’s announcement earlier this month and parallels what insulin sponsors did – but almost in reverse. For inhalers, political pressure on out-of-pocket costs has produced copay caps in the commercial market first, not Medicare.